← Back to Clinical Trials
RecruitingNCT03209414

Frailty Syndrome in Daily Practice of Interventional Cardiology Ward

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionFrail Elderly Syndrome
SponsorMedical University of Silesia
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment1,000
SexALL
Min Age65 Years
Max AgeN/A
Start Date2017-05-17
Completion2024-12-31

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The impact of frailty on immediate and long term outcomes of invasive treatment of coronary artery disease is not fully characterized. The assessment of frailty may help physicians in the selection of best treatment option and in the timing and modality of the follow-up. The FRAilty syndrome in daily Practice of Interventional CArdiology ward (FRAPICA) study is designed with the aim to validate the use of the Fried frailty scale and instrumental activities of daily living scale (IADL) as prognostic tools in patients admitted to hospital for symptomatic coronary artery disease, either stable, unstable, or acute coronary syndrome (ACS). The FRAPICA study is a single center prospective study enrolling patients aged ≥65 years. The aims are (1) to describe Fried frailty scale and IADL scale distribution before hospital discharge and (2) to investigate the prognostic role of Fried frailty and IADL scores. The outcomes are: (1) results of invasive treatment, (2) its complications (periinterventional MI, contrast-induced nephropathy, blood loss), (3) three-year all-cause mortality, cardiovascular mortality, stroke, myocardial infarction, reintervention, heart failure, hospital readmission for any cause, and a composite of the above mentioned. Ancillary analyses will be focused on different clinical presentations, different tools to assess frailty and risk stratification. The FRAPICA program will fill critical gaps in the understanding of the relation between frailty, cardiovascular disease, interventional procedures and outcome. It will enable more personalized risk assessment and identification of new targets for interventions.

Eligibility Criteria

Inclusion Criteria: * aged ≥ 65 * symptomatic coronary artery disease A) stable B) unstable C) NSTEMI D) STEMI * written, informed consent Exclusion Criteria: * lack of consent

Related Trials